BioCentury
ARTICLE | Clinical News

Matinas reports Phase II data of MAT2203 for vulvovaginal candidiasis

July 13, 2017 11:16 PM UTC

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported top-line data from a Phase II trial to treat moderate to severe vulvovaginal candidiasis showing that oral CAmB (MAT2203) met the primary safety endpoint but missed the secondary efficacy endpoints compared to oral fluconazole. The single-blind, U.S. trial evaluated once-daily 200 and 400 mg doses of MAT2203 for 5 days. The safety population included 137 women, while efficacy was evaluated in the modified intent-to-treat (ITT) population of 79 women with confirmed vulvovaginal candidiasis.

MAT2203 was well tolerated with no serious adverse events reported. Treatment-related adverse events were reported in 20% of patients receiving low-dose MAT2203 and 18% of patients receiving high-dose MAT2203 compared to 2% of patients receiving fluconazole. The most frequent MAT2203-related adverse events were gastrointestinal...

BCIQ Company Profiles

Matinas BioPharma Holdings Inc.

BCIQ Target Profiles

Ergosterol